ATS 2019 Virtual Final Program

P508 Bone Mineral Density and Ocular Safety After 52 Weeks’ Treatment with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Using Co-Suspension Delivery Technology in COPD/ E.M. Kerwin, G.T. Ferguson, M. Mo, K. DeAngelis, P. Dorinsky, Medford, OR, p.A3319 P509 Comparative Efficacy of Once-Daily Umeclidinium and Twice-Daily Salmeterol in Symptomatic Patients with Chronic Obstructive Pulmonary Disease Free of Inhaled Corticosteroids: Results from the EMAX Trial/ E.M. Kerwin, C. Vogelmeier, L. Bjermer, F. Maltais, M.L. Watkins, L. Tombs, I. Naya, I. Boucot, D.A. Lipson, C. Compton, P. Jones, Medford, OR, p.A3320 P510 Pharmacokinetics and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate in Adults with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Phase I, Open-Label, Single-Center Study/ P. Dorinsky, L.J. Dunn, K. DeAngelis, M. Mo, M. Gillen, Durham, NC, p.A3321 P511 Clinical Efficacy of a Selective Phosphodiesterase-4 Inhibitor (Roflumilast) in Patients with Chronic Obstructive Pulmonary Disease and Metabolic Syndrome/ G. Ignatova, E. Blinova, Chelyabinsk, Russian Federation, p.A3322 P512 Safety and Efficacy of Roflumilast in Chronic Obstructive Pulmonary Disease: An Updated Meta-Analysis of Randomized Controlled Trials/ M. Barbarawi, Y. Zayed, O. Barbarawi, E. Armstrong, A. Chahine, G. Bachuwa, Flint, MI, p.A3323 P513 Safety of Inhaled Corticosteroid Withdrawal in Elderly Patients Hospitalized for Chronic Obstructive Pulmonary Disease Exacerbation: A Nationwide Cohort Study in Japan/ T. Jo, Y. Yamauchi, T. Ando, H. Urushiyama, A. Mitani, S. Kunihiko, Y. Mikami, K. Hosoki, G. Tanaka, H. Matsui, H. Yasunaga, T. Nagase, Tokyo, Japan, p.A3324 P514 The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: A Pre-Specified Analysis of Safety According to Age/ G.J. Criner, M. Dransfield, D.M.G. Halpin, M.K. Han, C.E. Jones, S. Kilbride, P. Lange, D.A. Lomas, F. Martinez, S. Pascoe, D. Singh, R. Wise, D.A. Lipson, Philadelphia, PA, p.A3325 P515 Effect of Age on Efficacy and Safety of Multiple Inhaler Triple Therapy with Umeclidinium Added to Fluticasone Furoate/Vilanterol in Chronic Obstructive Pulmonary Disease/ T. Soule, S. Caveney, L. Tombs, I. Boucot, Research Triangle Park, NC, p.A3326 P516 Tolerance and Safety of Humidified High-Flow Nasal Cannula Oxygen Therapy in Patients Hospitalized with an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)/ A. Pandya, G. Criner, J. So, M.R. Jacobs, J. Thomas, H. Criner, Philadelphia, PA, p.A3327 P517 Effects on Sleep of Home Humidified High Flow Nasal Cannula- Oxygen Therapy (HHFNC-O 2 ) After Recent Acute Exacerbation of COPD (AECOPD) Requiring Hospitalization/ A. Pandya, A. Ohri, G.J. Criner, M.E. Vega Sanchez, H. Criner, M.R. Jacobs, J. Thomas, Philadelphia, PA, p.A3328 P518 Impact of Smoking Status on Improvements in Lung Function with Umeclidinium/Vilanterol Vs Fluticasone Propionate/Salmeterol in Patients with COPD/ M.J. Asmus, L. Tombs, R. Ray, I. Naya, I. Boucot, Research Triangle Park, NC, p.A3329 P519 Efficacy and Safety of Inhaled Umeclidinium/Vilanterol in COPD According to Level of Airflow Limitation: A Post Hoc Analysis/ M.J. Asmus, L. Tombs, R. Ray, I. Naya, I. Boucot, Research Triangle Park, NC, p.A3330 P520 Inhaled Corticosteroids Dose Regimens: Therapeutic Relevance of Lipophilicity, Solubility, Dissolution and Absorption from the Lung/ P.T. Daley-Yates, Uxbridge, United Kingdom, p.A3331 P521 Effect of Endoscopic Lung Volume Reductions in Patients with Severe Emphysema - Single Center Experience/ M.H. Brutsche, T. Schneider, K. Kozu, L. Kern, F. Baty, St. Gallen, Switzerland, p.A3332 P522 Efficacy and Safety of Inhaled Triple Therapy Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Dual Therapies in Chinese Patients with Moderate-to-Very Severe COPD/ C. Wang, T. Yang, J. Kang, R. Chen, L. Zhao, H. He, P.N. Assam, R. Su, E. Bourne, S. Ballal, K. DeAngelis, P. Dorinsky, Beijing, China, p.A3333 P523 The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Cardiovascular Safety/ D.A. Lipson, G. Criner, M.T. Dransfield, D.M.G. Halpin, M.K. Han, C.E. Jones, S. Kilbride, P. Lange, D.A. Lomas, F.J. Martinez, S. Pascoe, D. Singh, R.A. Wise, Collegeville and Philadelphia, PA, p.A3334 P524 Is Triple Therapy in a Single MDI Inhaler Superior to Standard Treatment in Patients with Stable COPD? A 6 Month Prospective Cohort Crossover Study with Patients Acting as Their Own Controls/ S. Rustscheff, Varnamo, Sweden, p.A3335 P525 Adherence to Maintenance Medications Among Chinese Chronic Obstructive Pulmonary Disease (COPD) Patients: A Retrospective Claims Database Study/ R. Chen, Y. Gao, H. Wang, N. Shen, H. Shang, X. You, X. Ling, J. Xuan, Guangzhou, China, p.A3336 P526 Medication Effect in COPD Patients Coexistent with Heart Failure/ V.Y.-F. Su, K.-Y. Yang, Taipei, Taiwan, p.A3337 P527 Non-Pharma Management of COPD in Primary Care: Guideline Implementation a Continuing Challenge/ R.M. Angus, L. Davies, E. McKnight, P. England, K. Sheridan, K. Sargeant, M. Pearson, Liverpool, United Kingdom, p.A3338 P528 The IMPACT Trial: Single Inhaler Triple Therapy fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Analysis According to Smoking Status/ D.M.G. Halpin, S. Bardsley, G. Criner, M. Dransfield, M.K. Han, C.E. Jones, S. Kilbride, D.A. Lomas, F. Martinez, S. Pascoe, D. Singh, R. Wise, D.A. Lipson, P. Lange, Exeter, United Kingdom, p.A3339 ATS 2019 • Dallas, TX 162 MONDAY • MAY 20